CAR-T Therapy in China: Questions for International Patients

Who might be eligible?

CAR-T eligibility depends on the exact diagnosis, prior therapies, performance status, organ function, product authorization and treating team assessment. Seek an individualized decision from a qualified hematology/oncology team.

Which costs should be compared?

Do not compare only the medicine price. Request an itemized estimate including screening, cell collection, manufacturing/product costs where relevant, bridging therapy, conditioning, admission, toxicity management and follow-up.

Can China and US costs be compared directly?

Only when the country, year, product, indication, treatment setting, payer versus patient cost, and included services are stated. This website does not publish unverified comparative prices.

What records should be prepared?

A hematopathology report, staging and treatment history, recent laboratory and imaging records, medications and contact details for your current clinical team may be requested.

What are important safety questions?

Ask about infection risk, cytokine-release syndrome, neurotoxicity, emergency capabilities, caregiver needs and follow-up before any travel decision.

Sources and further reading

General clinical context; not proof of any individual hospital service.

• NCI — T-cell transfer therapy
• NCI — immunotherapy side effects